The controversy of a wider statin utilization: Why?

Expert Opinion on Drug Safety

Volumn 12, Issue 3, 2013, Pages 327-337

  Mansi, Ishak ^a,c,d   Mortensen, Eric ^b,e  

^a SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

^b VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Adverse events; Hyperlipidemia; Observational studies; Randomized controlled trials; Statin

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PRAVASTATIN; PROTEIN SERINE THREONINE KINASE;

ACUTE PANCREATITIS; BASIC RESEARCH; BONE DENSITY; CANCER RISK; CATARACT; CLINICAL ASSESSMENT; COGNITION; DIABETES MELLITUS; DRUG UTILIZATION; ERECTILE DYSFUNCTION; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYDROPHILICITY; INTRAOCULAR HEMORRHAGE; KIDNEY DYSFUNCTION; LIPID SOLUBILITY; LIPOPHILICITY; LIVER TOXICITY; MEMORY DISORDER; MENTAL DETERIORATION; META ANALYSIS (TOPIC); MUSCLE WEAKNESS; MUSCULOSKELETAL PAIN; OBSERVATIONAL STUDY; PERIPHERAL NEUROPATHY; PREDICTION; PRIMARY PREVENTION; PROPENSITY SCORE; PSYCHOLOGICAL WELL BEING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; RISK REDUCTION;

DRUG TOXICITY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84876553028     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2013.779667     Document Type: Review

References (109)

1. Blaha MJ, Nasir K, Blumenthal RS. Statin therapy for healthy men identified as "increased risk". JAMA 2012;307:1489-90
2. Redberg RF, Katz MH. Healthy men should not take statins. JAMA 2012;307:1491-2
3. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39 (Pubitemid 38924592)
4. Komachi Y, Iida M, Shimamoto T, et al. Geographic and occupational comparisons of risk factors in cardiovascular diseases in Japan. Jpn Circ J 1971;35:189-207
5. Report of the Committee of Principal Investigators. W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Lancet 1980;2:379-85
6. Muldoon MF, Manuck SB, Mendelsohn AB, et al. Cholesterol reduction and non-illness mortality: meta-analysis of randomised clinical trials. BMJ 2001;322:11-15 (Pubitemid 32066249)
7. Jacobs D, Blackburn H, Higgins M, et al. Report of the conference on low blood cholesterol: mortality associations. Circulation 1992;86:1046-60
8. Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 2008;8:373-418
9. Kiortsis DN, Filippatos TD, Mikhailidis DP, et al. Statin-associated adverse effects beyond muscle and liver toxicity. Atherosclerosis 2007;195:7-16 (Pubitemid 47561937)
10. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 2010;340:c2197
11. Boudreau DM, Yu O, Johnson J. Statin use and cancer risk: a comprehensive review. Expert Opin Drug Saf 2010;9:603-21
12. Staal A, Frith JC, French MH, et al. The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity. J Bone Miner Res 2003;18:88-96 (Pubitemid 36008343)
13. Chung YS, Lee MD, Lee SK, et al. HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab 2000;85:1137-42
14. Young-Xu Y, Chan KA, Liao JK, et al. Long-term statin use and psychological well-being. J Am Coll Cardiol 2003;42:690-7 (Pubitemid 37000187)
15. Hyyppa MT, Kronholm E, Virtanen A, et al. Does simvastatin affect mood and steroid hormone levels in hypercholesterolemic men A randomized double-blind trial. Psychoneuroendocrinology 2003;28:181-94 (Pubitemid 36044077)
16. Ormiston T, Wolkowitz OM, Reus VI, et al. Behavioral implications of lowering cholesterol levels: a double-blind pilot study. Psychosomatics 2003;44:412-14 (Pubitemid 37071929)
17. Yang CC, Jick SS, Jick H. Lipid-lowering drugs and the risk of depression and suicidal behavior. Arch Intern Med 2003;163:1926-32 (Pubitemid 37082704)
18. Beck P, Wysowski DK, Downey W, et al. Statin use and the risk of breast cancer. J Clin Epidemiol 2003;56:280-5 (Pubitemid 36513491)
19. Setoguchi S, Glynn RJ, Avorn J, et al. Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation 2007;115:27-33 (Pubitemid 46058608)
20. Marelli C, Gunnarsson C, Ross S, et al. Statins and risk of cancer: a retrospective cohort analysis of 45,857 matched pairs from an electronic medical records database of 11 million adult Americans. J Am Coll Cardiol 2011;58:530-7
21. Karp I, Behlouli H, Lelorier J, et al. Statins and cancer risk. Am J Med 2008;121:302-9 (Pubitemid 351417853)
22. Hanson J, Bossingham D. Lupus-like syndrome associated with simvastatin. Lancet 1998;352:1070
23. Noel B, Panizzon RG. Lupus-like syndrome associated with statin therapy. Dermatology 2004;208:276-7 (Pubitemid 38594552)
24. Fernandez G, Spatz ES, Jablecki C, et al. Statin myopathy: a common dilemma not reflected in clinical trials. Cleve Clin J Med 2011;78:393-403
25. McCarey DW, McInnes IB, Madhok R, et al. Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004;363:2015-21 (Pubitemid 38781100)
26. Beltowski J, Wojcicka G, Jamroz-Wisniewska A. Adverse effects of statins-mechanisms and consequences. Curr Drug Saf 2009;4:209-28
27. Chalmers JD, Singanayagam A, Murray MP, et al. Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am J Med 2008;121:1002-7
28. Frost FJ, Petersen H, Tollestrup K, et al. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 2007;131:1006-12 (Pubitemid 46608700)
29. Fernandez R, De Pedro VJ, Artigas A. Statin therapy prior to ICU admission: protection against infection or a severity marker Intensive Care Med 2006;32:160-4
30. Gao X, Simon KC, Schwarzschild MA, et al. Prospective study of statin use and risk of Parkinson disease. Arch Neurol 2012;69:380-4
31. Cenedella RJ. Cholesterol and cataracts. Surv Ophthalmol 1996;40:320-37 (Pubitemid 26046210)
32. Chodick G, Heymann AD, Flash S, et al. Persistence with statins and incident cataract: a population-based historical cohort study. Ann Epidemiol 2010;20:136-42
33. Fong DS, Poon KY. Recent statin use and cataract surgery. Am J Ophthalmol 2012;153:222-8
34. Mansi IA, Mortensen EM, Pugh MJ, et al. Incidence of musculoskeletal and neoplastic diseases in patients on statin therapy: results of a retrospective cohort analysis. Am J Med Sci 2012; [Epub ahead of print]
35. Meier CR, Schlienger RG, Kraenzlin ME, et al. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000;283:3205-10 (Pubitemid 30422037)
36. Goedeke L, Fernandez-Hernando C. Regulation of cholesterol homeostasis. Cell Mol Life Sci 2012;69:915-30
37. Martini C, Pallottini V. Cholesterol: from feeding to gene regulation. Genes Nutr 2007;2:181-93
38. Trapani L, Pallottini V. Hypercholesterolemia and 3-hydroxy 3-methylglutaryl Coenzyme A reductase regulation during ageing. Sci World J 2009;9:564-74
39. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002;109:1125-31 (Pubitemid 34496588)
40. Koh KK, Sakuma I, Quon MJ. Differential metabolic effects of distinct statins. Atherosclerosis 2011;215:1-8
41. Zhou Q, Liao JK. Pleiotropic effects of statins-Basic research and clinical perspectives. Circ J 2010;74:818-26
42. Chow SC. Immunomodulation by statins: mechanisms and potential impact on autoimmune diseases. Arch Immunol Ther Exp (Warsz) 2009;57:243-51
43. Matsumoto M, Einhaus D, Gold ES, et al. Simvastatin augments lipopolysaccharide-induced proinflammatory responses in macrophages by differential regulation of the c-Fos and c-Jun transcription factors. J Immunol 2004;172:7377-84 (Pubitemid 38747598)
44. Robey RW, To KK, Polgar O, et al. ABCG2: a perspective. Adv Drug Deliv Rev 2009;61:3-13
45. De Pinieux G, Chariot P, Ammi-Said M, et al. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol 1996;42:333-7 (Pubitemid 26284422)
46. Ramasubbu K, Estep J, White DL, et al. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol 2008;51:415-26
47. Deichmann R, Lavie C, Andrews S. Coenzyme q10 and statin-induced mitochondrial dysfunction. Ochsner J 2010;10:16-21
48. Zureik M, Courbon D, Ducimetiere P. Serum cholesterol concentration and death from suicide in men: paris prospective study I. BMJ 1996;313:649-51 (Pubitemid 26300599)
49. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ 1990;301:309-14 (Pubitemid 20238057)
50. Ben-Yehuda O, DeMaria AN. Low LDL-C levels and cancer reassuring but still not definitive. J Am Coll Cardiol 2008;52:1150-1
51. Alsheikh-Ali AA, Trikalinos TA, Kent DM, et al. Statins, low-density lipoprotein cholesterol, and risk of cancer. J Am Coll Cardiol 2008;52:1141-7
52. Steinberg D. Statin treatment does not cause cancer. J Am Coll Cardiol 2008;52:1148-9
53. Jacobs EJ, Gapstur SM. Cholesterol and cancer: answers and new questions. Cancer Epidemiol Biomarkers Prev 2009;18:2805-6
54. Thompson PD, Clarkson PM, Rosenson RS. An assessment of statin safety by muscle experts. Am J Cardiol 2006;97:69C-76C
55. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-90 (Pubitemid 37430274)
56. Marie I, Delafenetre H, Massy N, et al. Tendinous disorders attributed to statins: a study on ninety-six spontaneous reports in the period 1990-2005 and review of the literature. Arthritis Rheum 2008;59:367-72 (Pubitemid 351399207)
57. Carmont MR, Highland AM, Blundell CM, et al. Simultaneous bilateral achilles tendon ruptures associated with statin medication despite regular rock climbing exercise. Phys Ther Sport 2009;10:150-2
58. Beri A, Dwamena FC, Dwamena BA. Association between statin therapy and tendon rupture: a case-control study. J Cardiovasc Pharmacol 2009;53:401-4
59. Pullatt RC, Gadarla MR, Karas RH, et al. Tendon rupture associated with simvastatin/ezetimibe therapy. Am J Cardiol 2007;100:152-3 (Pubitemid 46970701)
60. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004;292:2585-90 (Pubitemid 39577514)
61. Draeger A, Monastyrskaya K, Mohaupt M, et al. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol 2006;210:94-102 (Pubitemid 44288185)
62. Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002;137:581-5
63. Yang KC, Chien JY, Tseng WK, et al. Statins do not improve short-term survival in an oriental population with sepsis. Am J Emerg Med 2007;25:494-501
64. Wagstaff LR, Mitton MW, Arvik BM, et al. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 2003;23:871-80 (Pubitemid 36875671)
65. Evans MA, Golomb BA. Statin-associated adverse cognitive effects: survey results from 171 patients. Pharmacotherapy 2009;29:800-11
66. Muldoon MF, Ryan CM, Sereika SM, et al. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med 2004;117:823-9 (Pubitemid 39602790)
67. Alsheikh-Ali AA, Maddukuri PV, Han H, et al. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol 2007;50:409-18 (Pubitemid 47096680)
68. Mason RP, Walter MF, Day CA, et al. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. Am J Cardiol 2005;96:11F-23F (Pubitemid 41207729)
69. Hsiang B, Zhu Y, Wang Z, et al. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 1999;274:37161-8
70. Yamazaki M, Akiyama S, Ni'inuma K, et al. Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter. Drug Metab Dispos 1997;25:1123-9 (Pubitemid 27446581)
71. Vgontzas AN, Kales A, Bixler EO, et al. Effects of lovastatin and pravastatin on sleep efficiency and sleep stages. Clin Pharmacol Ther 1991;50:730-7
72. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16
73. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35 (Pubitemid 40471450)
74. Kemmler G, Hummer M, Widschwendter C, et al. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Arch Gen Psychiatry 2005;62:1305-12 (Pubitemid 41746608)
75. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207
76. Launer LJ, Wind AW, Deeg DJ. Nonresponse pattern and bias in a community-based cross-sectional study of cognitive functioning among the elderly. Am J Epidemiol 1994;139:803-12 (Pubitemid 24135784)
77. Palmer SC, Craig JC, Navaneethan SD, et al. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012;157:263-75
78. Taylor F, Ward K, Moore TH, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2011;CD004816
79. Psaty BM, Furberg CD, Ray WA, et al. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis. JAMA 2004;292:2622-31 (Pubitemid 39577518)
80. Jacobson TA. Toward "pain-free" statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc 2008;83:687-700 (Pubitemid 351810569)
81. Hsia J, MacFadyen JG, Monyak J, et al. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol < 50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatini J Am Coll Cardiol 2011. 57.1666-75.
82. Buettner C, Rippberger MJ, Smith JK, et al. Statin use and musculoskeletal pain among adults with and without arthritis. Am J Med 2012;125:176-82
83. Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther 2005;19:403-14 (Pubitemid 43228152)
84. Buettner C, Davis RB, Leveille SG, et al. Prevalence of musculoskeletal pain and statin use. J Gen Intern Med 2008;23:1182-6
85. FDA Drug Safety Communication. New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. U.S. Food and Drug Administration; 2011, http://www.fda.gov/Drugs/DrugSafety/ ucm256581.htm (Accessed June 8, 2011
86. FDA Drug Safety Communication. Important safety label changes to cholesterol-lowering statin drugs. The U.S. Food and Drug Administration; 2012, http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm (Accessed March 1, 2012
87. Hoffman R, Lim H. Observational study design. In: Ambrosius W, editor. Topics in biostatistics. Humana Press, New Jersey; 2007. p. 19-30
88. Hemmila MR, Birkmeyer NJ, Arbabi S, et al. Introduction to propensity scores: a case study on the comparative effectiveness of laparoscopic vs open appendectomy. Arch Surg 2010;145:939-45
89. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
90. Schneeweiss S, Seeger JD, Maclure M, et al. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001;154:854-64 (Pubitemid 33000813)
91. Perkins AJ, Kroenke K, Unutzer J, et al. Common comorbidity scales were similar in their ability to predict health care costs and mortality. J Clin Epidemiol 2004;57:1040-8 (Pubitemid 39446643)
92. Chen D, Restrepo MI, Fine MJ, et al. Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia. Am J Respir Crit Care Med 2011;184:312-16
93. Boudreau DM, Yu O, Johnson J. Statin use and cancer risk: a comprehensive review. Expert Opin Drug Saf 2010;9:603-21
94. Brookhart MA, Patrick AR, Dormuth C, et al. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol 2007;166:348-54 (Pubitemid 47216808)
95. Dormuth CR, Patrick AR, Shrank WH, et al. Statin adherence and risk of accidents: a cautionary tale. Circulation 2009;119:2051-7
96. McWilliams JM, Zaslavsky AM, Meara E, et al. Impact of medicare coverage on basic clinical services for previously uninsured adults. JAMA 2003;290:757-64 (Pubitemid 37432952)
97. Friedman E. The uninsured. From dilemma to crisis. JAMA 1991;265:2491-5
98. McWilliams JM. Health consequences of uninsurance among adults in the United States: recent evidence and implications. Milbank Q 2009;87:443-94
99. Glantz S, Slinker B. Primer of applied regression and analysis of variance. 2nd edition. McGraw-Hill, Inc, New York; 2001
100. Raphael KG, Cloitre M. Does mood-congruence or causal search govern recall bias A test of life event recall. J Clin Epidemiol 1994;47:555-64 (Pubitemid 24171220)
101. Elwood M. Critical appraisal of epidemiological studies and clinical trials. 3rd edition. Oxford University Press, Oxford; 2007
102. Weitzen S, Lapane KL, Toledano AY, et al. Principles for modeling propensity scores in medical research: a systematic literature review. Pharmacoepidemiol Drug Saf 2004;13:841-53 (Pubitemid 40003819)
103. Patrick AR, Schneeweiss S, Brookhart MA, et al. The implications of propensity score variable selection strategies in pharmacoepidemiology: an empirical illustration. Pharmacoepidemiol Drug Saf 2011;20:551-9
104. Oberg AL, Mahoney DW. Linear mixed effects models. In: Ambrosius W, editor. Topics in biostatistics. Humana Press, New Jersey; 2007. p. 213-35
105. Campbell M. Statistics at square two: understanding modern statistical applications in medicine. 1st edition. BMJ Publishing Group, London; 2001
106. Toh S, Hernandez-Diaz S. Statins and fracture risk. A systematic review. Pharmacoepidemiol Drug Saf 2007;16:627-40 (Pubitemid 47039529)
107. Fairman KA, Curtiss FR. Still looking for health outcomes in all the wrong places Misinterpreted observational evidence, medication adherence promotion, and value-based insurance design. J Manag Care Pharm 2009;15:501-7
108. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72 (Pubitemid 351831357)
109. Varma J, Rodriguez R, Mansi IA. Reasoning and evidence-based medicine: common pitfalls. South Med J 2012;105:167-72